<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11461068</article-id><article-id pub-id-type="pmc">2364048</article-id><article-id pub-id-type="pii">6691871</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1871</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Helle</surname><given-names>S I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Geisler</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Anker</surname><given-names>G B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leirvaag</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Holly</surname><given-names>J M P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f8;nning</surname><given-names>P E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Oncology, Haukeland University Hospital, Bergen, N-5021, Norway</aff><aff id="aff2"><label>2</label>Division of Surgery, Bristol Royal Infirmary, Bristol, BS2 HW, UK</aff><pub-date pub-type="ppub"><month>07</month><year>2001</year></pub-date><volume>85</volume><issue>2</issue><fpage>147</fpage><lpage>151</lpage><history><date date-type="received"><day>25</day><month>09</month><year>2000</year></date><date date-type="rev-recd"><day>14</day><month>03</month><year>2001</year></date><date date-type="accepted"><day>27</day><month>03</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Alterations in the insulin-like growth factor (IGF)-system were evaluated in 16 patients treated with diethylstilboestrol 5&#x02008;mg 3 times daily. Fasting blood samples were obtained before treatment and after 2 weeks, 1 month and/or 2&#x02013;3 months on therapy. Insulin-like growth factor (IGF)-I, IGF-II, free IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-2 and IGFBP-3 were measured by radioimmuno-/immunoradiometric-assays. All samples were subjected to Western ligand blotting as well as immunoblotting for IGFBP-3. We observed a significant decrease (percentage of pretreatment levels with 95 confidence intervals of the mean) in IGF-I [2 weeks 63&#x00025; (49&#x02013;79); 1 month 56&#x00025; (44&#x02013;73); 2&#x02013;3 months 66&#x00025; (53&#x02013;82)], IGF-II [2 weeks 67&#x00025; (56&#x02013;80); 1 month 60&#x00025; (52&#x02013;68); 2&#x02013;3 months 64&#x00025; (55&#x02013;75)], free IGF-I [2 weeks 29&#x00025; (19&#x02013;42); 1 month 25&#x00025; (18&#x02013;36); 2&#x02013;3 months 31&#x00025; (21&#x02013;46)], IGFBP-2 [2 weeks 53&#x00025; (18&#x02013;156); 1 month 69&#x00025; (61&#x02013;78); 2&#x02013;3 months 66&#x00025; (57&#x02013;78)], IGFBP-3 [2 weeks 74&#x00025; (63&#x02013;85); 1 month 69&#x00025; (62&#x02013;76); 2&#x02013;3 months 71&#x00025; (63&#x02013;80)], as well as IGFBP-3 protease activity [2 weeks 71&#x00025; (54&#x02013;95); 1 month 78&#x00025; (64&#x02013;94); 2&#x02013;3 months 71&#x00025; (54&#x02013;93)]. Contrary, the plasma levels (percentage of pretreatment levels with 95 confidence intervals of the mean) of IGFBP-1 [2 weeks 250&#x00025; (127&#x02013;495); 1 month 173&#x00025; (138&#x02013;542); 2&#x02013;3 months 273&#x00025; (146&#x02013;510)] and IGFBP-4 [2 weeks 146&#x00025; (112&#x02013;192); 1 month 140&#x00025; (116&#x02013;169); 2&#x02013;3 months 150&#x00025; (114&#x02013;198)] increased significantly. While this study confirms previous observations during treatment with oral oestrogens in substitution doses, the reduction in plasma IGF-II, free IGF-I, IGFBP-2 and -3 are all novel findings. A profound decrease in free IGF-I suggests a reduced bioavailability of IGFs from plasma to the tissues. These observations may be of significance to understand the mechanisms of the antitumour effect of diethylstilboestrol in pharmacological doses. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>high dose oestrogens</kwd><kwd>breast cancer therapy</kwd><kwd>IGF-system</kwd></kwd-group></article-meta></front></article>


